Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rallybio Corporaton (RLYB)

Rallybio Corporaton (RLYB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 66,733
  • Shares Outstanding, K 41,449
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,560 K
  • 60-Month Beta -1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.75
Trade RLYB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.42
  • Number of Estimates 2
  • High Estimate -0.37
  • Low Estimate -0.46
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5400 +11.04%
on 04/25/24
2.0000 -14.50%
on 05/16/24
-0.0600 (-3.39%)
since 04/22/24
3-Month
1.4550 +17.53%
on 03/27/24
3.4600 -50.58%
on 04/11/24
-0.1200 (-6.56%)
since 02/22/24
52-Week
1.2250 +39.59%
on 02/05/24
9.1400 -81.29%
on 06/07/23
-5.0900 (-74.85%)
since 05/22/23

Most Recent Stories

More News
Stock Index Futures are Higher after Wholesale Prices Increased Less Than Expected in March

June S&P 500 E-Mini futures (ESM24) are up 0.02%, and June Nasdaq 100 E-Mini futures (NQM24) are up 0.17%% this morning, after the release of the PPI data.

ESM24 : 5,328.00s (-0.32%)
NQM24 : 18,786.75s (-0.07%)
DECK : 892.94 (-0.76%)
MCHP : 99.49 (+3.87%)
ADI : 240.16 (+10.86%)
MNDY : 246.44 (+2.07%)
NVDA : 949.50 (-0.46%)
JPM : 198.31 (-0.61%)
WFC : 60.93 (-0.86%)
C : 63.82 (-1.42%)
GLE.FP : 27.250 (-0.71%)
RLYB : 1.7100 (+6.21%)
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 1.7100 (+6.21%)
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis

Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from human plasma for the prevention of FNAIT....

RLYB : 1.7100 (+6.21%)
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of...

RLYB : 1.7100 (+6.21%)
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)

Rallybio Corporation (RLYB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings...

RLYB : 1.7100 (+6.21%)
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 1.7100 (+6.21%)
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and...

RLYB : 1.7100 (+6.21%)
Rallybio to Present at Upcoming Investor Conferences in March

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 1.7100 (+6.21%)
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...

RLYB : 1.7100 (+6.21%)
EYPT : 11.47 (-1.04%)
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 1.7100 (+6.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

See More

Key Turning Points

3rd Resistance Point 1.8100
2nd Resistance Point 1.7700
1st Resistance Point 1.7400
Last Price 1.7100
1st Support Level 1.6700
2nd Support Level 1.6300
3rd Support Level 1.6000

See More

52-Week High 9.1400
Fibonacci 61.8% 6.1165
Fibonacci 50% 5.1825
Fibonacci 38.2% 4.2485
Last Price 1.7100
52-Week Low 1.2250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar